• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Inogen Inc

    5/4/26 4:11:54 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    S-8 1 ingn-20260504.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 4, 2026

    Registration Statement No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

    Inogen, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    33-0989359

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    500 Cummings Center, Suite 2800

    Beverly, Massachusetts 01915

    (Address of principal executive offices)

    Inducement Equity Awards

    (Full title of the plan)

    Kevin Smith

    Chief Executive Officer and President

    Inogen, Inc.

    500 Cummings Center, Suite 2800

    Beverly, Massachusetts 01915

    (Name and address of agent for service)

    (805) 562-0500

    (Telephone number, including area code, of agent for service)

    Copies to:

    Sarah C. Griffiths
    Covington & Burling LLP
    One International Place, Suite 1020
    Boston, MA 02110
    Telephone: (617) 603-8800

    Kevin P. Smith
    General Counsel
    Inogen, Inc.
    500 Cummings Center, Suite 2800

    Beverly, Massachusetts 01915

    Telephone: (877) 466-4364

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☒

     

     

     Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    This Registration Statement registers on Form S-8 (the “Registration Statement”) 281,897 shares of common stock, par value $0.001 per share (“Common Stock”), issuable to two employees pursuant to time-based restricted stock unit awards and performance-based restricted stock unit awards granted to each employee to induce such employee to accept employment with the Registrant in accordance with Nasdaq Listing Rule 5635(c)(4) (collectively, the “2026 Inducement Awards”). The 2026 Inducement Awards were approved by the Registrant’s Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The 2026 Inducement Awards were granted outside of the Registrant’s existing equity incentive plans. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Securities and Exchange Commission (the “Commission”), the information specified in Part I of Form S-8 has been omitted from this Registration Statement.

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance therewith files reports, proxy statements and other information with the Commission. The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Commission:

     

    (1) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 27, 2026 (the “Annual Report”);

    (2) All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report (other than the portions of these documents not deemed to be filed); and

    (3) The description of the Registrant’s common stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-36309) filed with the Commission on February 10, 2014, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

     


     

    Section 145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in its best interests, and, with respect to any criminal action, had no reasonable cause to believe the person’s actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise. The certificate of incorporation of the Registrant provides for the indemnification of the Registrant’s directors and officers to the fullest extent permitted under the Delaware General Corporation Law. In addition, the bylaws of the Registrant require the Registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director, or officer of the Registrant, or is or was a director or officer of the Registrant serving at the Registrant’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock repurchases, redemptions or other distributions or (4) for any transaction from which the director derived an improper personal benefit. The Registrant’s certificate of incorporation provides that the Registrant’s directors shall not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the Registrant’s directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

    Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

    As permitted by the Delaware General Corporation Law, the Registrant has entered into separate indemnification agreements with each of the Registrant’s directors and certain of the Registrant’s officers which require the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors, officers or certain other employees.

    The Registrant maintains insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.

    These indemnification provisions and the indemnification agreements entered into between the Registrant and the Registrant’s officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

     


     

     

    Item 8. Exhibits.

     

     

     

    Incorporated by Reference

    Exhibit
    Number

    Description

    Form

    File No.

    Exhibit

    Filing Date

      4.1

    Specimen common stock certificate of Registrant.

    S-1/A

    333-192605

    4.1

    1/16/14

      5.1*

    Opinion of Covington & Burling LLP.

     

     

     

     

    23.1*

    Consent of Deloitte and Touche, LLP, Independent Registered Public Accounting Firm.

     

     

     

     

    23.2*

    Consent of Opinion of Covington & Burling LLP (contained in Exhibit 5.1 hereto).

     

     

     

     

    24.1*

    Power of Attorney (contained on signature page hereto).

     

     

     

     

    99.1+*

    Form of Inducement Award Restricted Stock Unit Agreement - Time-Based.

     

     

     

     

    99.2+*

    Form of Inducement Award Restricted Stock Unit Agreement - Performance-Based.

     

     

     

     

    107*

    Filing Fee Table.

     

     

     

     

    + Indicates management contract or compensatory plan, contract or arrangement.

    * Filed herewith.

    Item 9. Undertakings.

    A. The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     


     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under “Item 6-Indemnification of Directors and Officers,” or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Beverly, Commonwealth of Massachusetts, on May 4, 2026.

    INOGEN, INC.

     

     

    By:

    /s/ Kevin Smith

     

    Kevin Smith

     

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kevin Smith and Jason Richardson, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of Inogen, Inc.) to sign the Registration Statement on Form S-8 of Inogen, Inc., and any and all amendments (including post-effective amendments) thereto, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

    /s/ Kevin Smith

     

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

     

    May 4, 2026

    Kevin Smith

     

     

    /s/ Jason Richardson

     

    Chief Financial Officer

    (Principal Accounting and Financial Officer)

     

    May 4, 2026

     

    Jason Richardson

     

     

    /s/ Elizabeth Mora

     

    Chairperson of the Board

     

    May 4, 2026

     

    Elizabeth Mora

     

     

    /s/ Glenn Boehnlein

     

    Director

     

    May 4, 2026

    Glenn Boehnlein

     

     

     

     

    /s/ Kevin King

     

    Director

     

    May 4, 2026

    Kevin King

     

     

     

     

    /s/ Mary Katherine Ladone

     

    Director

     

    May 4, 2026

    Mary Katherine Ladone

     

     

     

     

    /s/ Heather Rider

     

    Director

     

    May 4, 2026

    Heather Rider

     

     

     

     

    /s/ Mira Sahney

     

    Director

     

    May 4, 2026

    Mira Sahney

     

     

     

     

     

     


    Get the next $INGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inogen Announces First Quarter 2026 Financial Results

    Reported first quarter year-over-year revenue growth of 3.4% Company reiterates full-year 2026 guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance. "Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond," said Kevin Smith, Inogen's Chief Executive Officer. "Our progress reflects the

    5/7/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report First Quarter 2026 Financial Results on May 7, 2026

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    4/23/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces the Appointment of Vafa Jamali to Board of Directors

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Vafa Jamali as an independent director to the Inogen Board of Directors (the "Board"), effective on the date of the Company's 2026 Annual Meeting, or June 15th if earlier. Mr. Jamali is a long-time medical device executive who will bring added depth and expertise to the Board. During his tenure as the Chief Executive Officer of ZimVie, he led the company's Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support

    4/6/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by Needham with a new price target

    Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00

    5/22/25 8:16:14 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by William Blair

    William Blair upgraded Inogen from Mkt Perform to Outperform

    2/15/24 6:28:38 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $70,313 worth of shares (10,770 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 40% to 15,977 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    6/2/26 4:30:18 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Richardson Jason Andrew

    4 - Inogen Inc (0001294133) (Issuer)

    4/8/26 4:59:10 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Richardson Jason Andrew

    3 - Inogen Inc (0001294133) (Issuer)

    4/8/26 4:58:01 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    SEC Filings

    View All

    SEC Form SD filed by Inogen Inc

    SD - Inogen Inc (0001294133) (Filer)

    5/28/26 4:15:03 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Inogen Inc

    10-Q - Inogen Inc (0001294133) (Filer)

    5/8/26 4:10:59 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Inogen Inc (0001294133) (Filer)

    5/7/26 4:13:22 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces the Appointment of Vafa Jamali to Board of Directors

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Vafa Jamali as an independent director to the Inogen Board of Directors (the "Board"), effective on the date of the Company's 2026 Annual Meeting, or June 15th if earlier. Mr. Jamali is a long-time medical device executive who will bring added depth and expertise to the Board. During his tenure as the Chief Executive Officer of ZimVie, he led the company's Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support

    4/6/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth

    Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Appointed Vice President, U.S. Business to Business Sales Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson Appointed Chief Financial Officer Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. M

    3/30/26 4:00:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces the Appointment of Naga Rameswamy as Chief Technology Officer

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume

    9/25/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces First Quarter 2026 Financial Results

    Reported first quarter year-over-year revenue growth of 3.4% Company reiterates full-year 2026 guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2026 and reiterated its full-year guidance. "Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond," said Kevin Smith, Inogen's Chief Executive Officer. "Our progress reflects the

    5/7/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report First Quarter 2026 Financial Results on May 7, 2026

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    4/23/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook

    Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

    2/24/26 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inogen Inc

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    11/14/24 11:12:09 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Inogen Inc

    SC 13G - Inogen Inc (0001294133) (Subject)

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care